Teleflex (NYSE:TFX) Announces Earnings Results

Teleflex (NYSE:TFX) announced its earnings results on Thursday. The medical technology company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.18, Briefing.com reports. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company had revenue of $548.30 million during the quarter, compared to analyst estimates of $536.91 million. During the same quarter last year, the firm posted $1.44 earnings per share. Teleflex’s revenue was up 32.3% compared to the same quarter last year. Teleflex updated its FY 2026 guidance to 6.250-6.550 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Teleflex says its strategic divestitures remain on track to close in H2 2026 (OEM HSR period expired and OEM expected to close in Q3), and it intends to use roughly $1.8 billion of net proceeds to fund up to a $1 billion share repurchase program and repay about $800 million of debt, with opportunistic buybacks to begin in Q2.
• First quarter continuing-operations revenue was $548.3M (GAAP +32.3%, pro forma adjusted constant currency +5.1%) while adjusted EPS was $1.39 (down 3.5% YoY), with adjusted operating margin at 18.1% reflecting near-term margin pressure from tariffs, logistics, the vascular intervention acquisition and remediation charges.
• Management disclosed two third‑party supplier recalls affecting components in some vascular interventional kits, has taken remediation provisions in Q1, and warns the recalls may cause elevated backorders in Q2 even though they do not currently expect a material full‑year revenue impact.
• 2026 guidance remains pro forma revenue growth of 4.5%–5.5% and adjusted EPS of $6.25–$6.55, but assumes about $90 million of stranded costs and a fully burdened operating margin near 19% (management estimates a ~23% steady‑state margin once TSAs/MSAs and separation impacts are realized, with meaningful EPS improvement expected in 2027).
• R&D momentum: the Freesolve drug‑eluting resorbable magnesium scaffold program (BIOMAG‑II) is enrolling ahead of plan with a late‑2027 EU readout expected and a U.S. pivotal (BIOMAG‑III) planned to start in 2026, representing a potential long‑term growth driver.

Teleflex Stock Up 1.1%

Shares of TFX stock traded up $1.49 during trading on Friday, reaching $133.17. The company’s stock had a trading volume of 947,217 shares, compared to its average volume of 1,030,809. Teleflex has a 1-year low of $100.18 and a 1-year high of $139.67. The stock’s 50-day moving average price is $119.44 and its 200 day moving average price is $116.73. The company has a market capitalization of $5.89 billion, a price-to-earnings ratio of -5.84, a P/E/G ratio of 0.96 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.01.

Teleflex Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were issued a $0.34 dividend. The ex-dividend date was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s payout ratio is -5.96%.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title
• Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title
• Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title
• Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title
• Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title

Hedge Funds Weigh In On Teleflex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UMB Bank n.a. raised its stake in shares of Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after acquiring an additional 113 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in Teleflex during the 4th quarter worth $45,000. Danske Bank A S acquired a new position in Teleflex during the 3rd quarter worth $54,000. State of Wyoming purchased a new stake in Teleflex during the 2nd quarter worth about $111,000. Finally, EverSource Wealth Advisors LLC increased its holdings in Teleflex by 108.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock worth $119,000 after purchasing an additional 521 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Analyst Upgrades and Downgrades

TFX has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday. Needham & Company LLC boosted their target price on Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Mizuho set a $140.00 price target on Teleflex in a research note on Friday. Raymond James Financial restated an “outperform” rating and set a $150.00 price target on shares of Teleflex in a research report on Friday. Finally, Zacks Research raised Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $142.86.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.